프로티아
Financials
Valuation Metrics
프로티아's Market Cap is ₩647B. At end of 2025 it was ₩804B. Ranked #1559 of 2,436 in KR market (top 64%), #910 of 1,649 on KOSDAQ (top 55%), #62 of 96 in Health Care Equipment & Services (top 65%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 64.66B KRW | KR#1,559/2,436 Sec#62/96 |
| Revenue | 16.25B KRW | KR#2,189/2,436 Sec#75/96 |
| Net Income | 4.74B KRW | KR#1,139/2,436 Sec#38/96 |
| Total Assets | 34.13B KRW | KR#2,302/2,436 Sec#86/96 |
| Net Assets | 31.69B KRW | KR#2,147/2,436 Sec#77/96 |
| Employees | 89 | KR#1,716/2,436 Sec#66/96 |
| Value | ||
| P/E | 13.65x | KR#921/2,436 Sec#25/96 |
| P/B | 2.04x | KR#1,949/2,436 Sec#68/96 |
| PEG | 0.37x | KR#628/2,436 Sec#25/96 |
| P/S | 3.98x | KR#2,085/2,436 Sec#68/96 |
| EV/EBITDA | 15.25x | KR#865/2,436 Sec#24/96 |
| FCF Yield | 4.65% | KR#888/2,436 Sec#24/96 |
| Profitability | ||
| ROE | 14.94% | KR#240/2,436 Sec#12/96 |
| ROA | 13.87% | KR#94/2,436 Sec#10/96 |
| Op. Margin | 25.05% | KR#86/2,436 Sec#7/96 |
| Revenue Growth | 41.77% | KR#354/2,436 Sec#14/96 |
| Earnings Growth | 36.95% | KR#641/2,436 Sec#26/96 |
| Financial Health | ||
| Debt Ratio | 107.72% | KR#387/2,436 Sec#16/96 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/96 |
| FCF | 3.00B KRW | KR#1,018/2,436 Sec#29/96 |
| Cash | 2.58B KRW | KR#2,194/2,436 Sec#88/96 |
| Current Ratio | 10.74x | KR#89/2,436 Sec#11/96 |
| Net Debt/EBITDA | -0.64x | KR#549/2,436 Sec#20/96 |
| Performance | ||
| 1Y Return | 30.22% | KR#342/2,436 Sec#7/96 |
| 1M Return | 26.61% | KR#80/2,436 Sec#5/96 |
| From 52W High | -27.14% | KR#318/2,436 Sec#8/96 |
| 1Y MDD | -42.06% | KR#596/2,436 Sec#19/96 |
| Trading | ||
| Volume | 32,327 shares | KR#1,607/2,436 Sec#71/96 |
| Foreign Own. | 2.05% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | 368 KRW | KR#1,041/2,436 Sec#29/96 |
| BPS | 2,460 KRW | KR#1,919/2,436 Sec#59/96 |
Company Info
Protia, established in 2000 and transferred its listing to the KOSDAQ Market in 2023, develops, manufactures, and sells medical devices based on core immunodiagnostic technology. The company produces and supplies human-use products with the world's highest number of simultaneous allergy diagnostic technologies, the first domestic pet products, and the first antibiotic susceptibility testing products utilizing a capacitance measurement method. Protia possesses development capabilities for 192-line allergy diagnostic products and pursues technological innovation by expanding into domestic and international markets. Protia is headquartered in Gangseo-gu, Seoul.